180 related articles for article (PubMed ID: 22303947)
1. Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
Prior AM; Thapa M; Hua DH
Mini Rev Med Chem; 2012 Apr; 12(4):326-36. PubMed ID: 22303947
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibitors and diabetic kidney disease.
Oates PJ
Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
[TBL] [Abstract][Full Text] [Related]
4. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q; Liu Q; Ouyang D
Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
[TBL] [Abstract][Full Text] [Related]
5. Aldose reductase inhibitors and diabetic complications.
Raskin P; Rosenstock J
Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
[No Abstract] [Full Text] [Related]
6. Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Kousaxidis A; Petrou A; Lavrentaki V; Fesatidou M; Nicolaou I; Geronikaki A
Eur J Med Chem; 2020 Dec; 207():112742. PubMed ID: 32871344
[TBL] [Abstract][Full Text] [Related]
7. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
8. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B.
Ottanà R; Paoli P; Cappiello M; Nguyen TN; Adornato I; Del Corso A; Genovese M; Nesi I; Moschini R; Naß A; Wolber G; Maccari R
Molecules; 2021 Jan; 26(2):. PubMed ID: 33435264
[TBL] [Abstract][Full Text] [Related]
9. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study.
Shehzad MT; Imran A; Njateng GSS; Hameed A; Islam M; Al-Rashida M; Uroos M; Asari A; Shafiq Z; Iqbal J
Bioorg Chem; 2019 Jun; 87():857-866. PubMed ID: 30551808
[TBL] [Abstract][Full Text] [Related]
10. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
Sambasivarao SV; Soni LK; Gupta AK; Hanumantharao P; Kaskhedikar SG
Bioorg Med Chem Lett; 2006 Feb; 16(3):512-20. PubMed ID: 16297625
[TBL] [Abstract][Full Text] [Related]
13. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.
Gupta SK; Tripathi PK
Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470
[TBL] [Abstract][Full Text] [Related]
14. [Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus].
Kakhnovskiĭ IM; Koroleva TV; Golubiatnikova GA; Kalinkina MA
Klin Med (Mosk); 1996; 74(3):56-8. PubMed ID: 8926708
[TBL] [Abstract][Full Text] [Related]
15. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Maccari R; Ottanà R
J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors.
Agrawal YP; Agrawal MY; Gupta AK
Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533
[TBL] [Abstract][Full Text] [Related]
17. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Kador PF; Wyman M; Oates PJ
Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
[TBL] [Abstract][Full Text] [Related]
18. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Podjarny A
Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
[TBL] [Abstract][Full Text] [Related]
19. The role of aldose reductase inhibitors in diabetic complications: recent trends.
Kaul CL; Ramarao P
Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322
[TBL] [Abstract][Full Text] [Related]
20. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
Yabe-Nishimura C
Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
